Cidara Therapeutics, Inc. (NASDAQ: CDTX) Stock Competitors & Peer Comparison
See CDTX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CDTX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CDTX | $221.38 | +0.00% | 5.6B | -19.77 | -$11.20 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CDTX vs VRTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas VRTX's P/E ratio is 25.35. In terms of profitability, CDTX's ROE is -0.37%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, CDTX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CDTX vs REGN Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas REGN's P/E ratio is 16.71. In terms of profitability, CDTX's ROE is -0.37%, compared to REGN's ROE of +0.18%. Regarding short-term risk, CDTX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
CDTX vs VRNA Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CDTX's ROE is -0.37%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, CDTX is similarly volatile compared to VRNA. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
CDTX vs ARGX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ARGX's P/E ratio is 78.75. In terms of profitability, CDTX's ROE is -0.37%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, CDTX is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
CDTX vs SGEN Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CDTX's ROE is -0.37%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CDTX is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CDTX vs RVMDW Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, CDTX's ROE is -0.37%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, CDTX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CDTX vs RVMD Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas RVMD's P/E ratio is -26.52. In terms of profitability, CDTX's ROE is -0.37%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, CDTX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
CDTX vs ONC Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ONC's P/E ratio is 70.70. In terms of profitability, CDTX's ROE is -0.37%, compared to ONC's ROE of +0.12%. Regarding short-term risk, CDTX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CDTX vs ALNY Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ALNY's P/E ratio is 37.02. In terms of profitability, CDTX's ROE is -0.37%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, CDTX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CDTX vs ROIV Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ROIV's P/E ratio is -34.86. In terms of profitability, CDTX's ROE is -0.37%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, CDTX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
CDTX vs INCY Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas INCY's P/E ratio is 16.06. In terms of profitability, CDTX's ROE is -0.37%, compared to INCY's ROE of +0.30%. Regarding short-term risk, CDTX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
CDTX vs BNTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas BNTX's P/E ratio is -19.61. In terms of profitability, CDTX's ROE is -0.37%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, CDTX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CDTX vs UTHR Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas UTHR's P/E ratio is 19.10. In terms of profitability, CDTX's ROE is -0.37%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CDTX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
CDTX vs MRNA Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas MRNA's P/E ratio is -6.73. In terms of profitability, CDTX's ROE is -0.37%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, CDTX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
CDTX vs INSM Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas INSM's P/E ratio is -17.15. In terms of profitability, CDTX's ROE is -0.37%, compared to INSM's ROE of -1.30%. Regarding short-term risk, CDTX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CDTX vs BGNE Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CDTX's ROE is -0.37%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, CDTX is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CDTX vs DNA-WT Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CDTX's ROE is -0.37%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CDTX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
CDTX vs GMAB Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas GMAB's P/E ratio is 20.77. In terms of profitability, CDTX's ROE is -0.37%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, CDTX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CDTX vs NBIX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas NBIX's P/E ratio is 24.10. In terms of profitability, CDTX's ROE is -0.37%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, CDTX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CDTX vs JAZZ Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, CDTX's ROE is -0.37%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, CDTX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CDTX vs BBIO Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas BBIO's P/E ratio is -21.41. In terms of profitability, CDTX's ROE is -0.37%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, CDTX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CDTX vs ASND Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ASND's P/E ratio is -100.79. In terms of profitability, CDTX's ROE is -0.37%, compared to ASND's ROE of -56.42%. Regarding short-term risk, CDTX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CDTX vs EXEL Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas EXEL's P/E ratio is 15.88. In terms of profitability, CDTX's ROE is -0.37%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, CDTX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CDTX vs KRTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CDTX's ROE is -0.37%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CDTX is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CDTX vs ARWR Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ARWR's P/E ratio is -39.37. In terms of profitability, CDTX's ROE is -0.37%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, CDTX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CDTX vs BMRN Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas BMRN's P/E ratio is 28.86. In terms of profitability, CDTX's ROE is -0.37%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, CDTX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CDTX vs TECH Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas TECH's P/E ratio is 37.16. In terms of profitability, CDTX's ROE is -0.37%, compared to TECH's ROE of +0.05%. Regarding short-term risk, CDTX is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CDTX vs RNAM Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CDTX's ROE is -0.37%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CDTX is similarly volatile compared to RNAM. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CDTX vs AXSM Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas AXSM's P/E ratio is -56.92. In terms of profitability, CDTX's ROE is -0.37%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, CDTX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CDTX vs MDGL Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas MDGL's P/E ratio is -36.51. In terms of profitability, CDTX's ROE is -0.37%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, CDTX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CDTX vs SMMT Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas SMMT's P/E ratio is -8.14. In terms of profitability, CDTX's ROE is -0.37%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, CDTX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CDTX vs KRYS Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas KRYS's P/E ratio is 45.60. In terms of profitability, CDTX's ROE is -0.37%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CDTX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CDTX vs HALO Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas HALO's P/E ratio is 17.87. In terms of profitability, CDTX's ROE is -0.37%, compared to HALO's ROE of +1.26%. Regarding short-term risk, CDTX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CDTX vs CYTK Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CYTK's P/E ratio is -13.23. In terms of profitability, CDTX's ROE is -0.37%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, CDTX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CDTX vs RXDX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CDTX's ROE is -0.37%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CDTX is less volatile compared to RXDX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
CDTX vs ABVX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ABVX's P/E ratio is -65.48. In terms of profitability, CDTX's ROE is -0.37%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CDTX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CDTX vs NUVL Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CDTX's ROE is -0.37%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CDTX is similarly volatile compared to NUVL. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CDTX vs CRNX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CRNX's P/E ratio is -16.28. In terms of profitability, CDTX's ROE is -0.37%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CDTX is less volatile compared to CRNX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CDTX vs PTGX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas PTGX's P/E ratio is -75.49. In terms of profitability, CDTX's ROE is -0.37%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, CDTX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CDTX vs IMGN Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CDTX's ROE is -0.37%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CDTX is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CDTX vs IONS Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas IONS's P/E ratio is -30.10. In terms of profitability, CDTX's ROE is -0.37%, compared to IONS's ROE of -1.11%. Regarding short-term risk, CDTX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CDTX vs PRAX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas PRAX's P/E ratio is -23.02. In terms of profitability, CDTX's ROE is -0.37%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, CDTX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CDTX vs SYRE Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas SYRE's P/E ratio is -47.27. In terms of profitability, CDTX's ROE is -0.37%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, CDTX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CDTX vs KYMR Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas KYMR's P/E ratio is -29.29. In terms of profitability, CDTX's ROE is -0.37%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, CDTX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
CDTX vs ALKS Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ALKS's P/E ratio is 52.66. In terms of profitability, CDTX's ROE is -0.37%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, CDTX is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CDTX vs BPMC Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CDTX's ROE is -0.37%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CDTX is similarly volatile compared to BPMC. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CDTX vs APGE Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas APGE's P/E ratio is -30.97. In terms of profitability, CDTX's ROE is -0.37%, compared to APGE's ROE of -0.33%. Regarding short-term risk, CDTX is less volatile compared to APGE. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CDTX vs CERE Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CERE's P/E ratio is -16.47. In terms of profitability, CDTX's ROE is -0.37%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CDTX is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CDTX vs TGTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas TGTX's P/E ratio is 17.88. In terms of profitability, CDTX's ROE is -0.37%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, CDTX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CDTX vs IMVT Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas IMVT's P/E ratio is -14.46. In terms of profitability, CDTX's ROE is -0.37%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, CDTX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CDTX vs PCVX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas PCVX's P/E ratio is -7.86. In terms of profitability, CDTX's ROE is -0.37%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, CDTX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CDTX vs IBRX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas IBRX's P/E ratio is -8.44. In terms of profitability, CDTX's ROE is -0.37%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, CDTX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
CDTX vs MTSR Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CDTX's ROE is -0.37%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, CDTX is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
CDTX vs MRUS Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CDTX's ROE is -0.37%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, CDTX is similarly volatile compared to MRUS. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CDTX vs RYTM Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas RYTM's P/E ratio is -31.71. In terms of profitability, CDTX's ROE is -0.37%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, CDTX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CDTX vs ACLX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CDTX's ROE is -0.37%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CDTX is less volatile compared to ACLX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CDTX vs COGT Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas COGT's P/E ratio is -18.45. In terms of profitability, CDTX's ROE is -0.37%, compared to COGT's ROE of -0.83%. Regarding short-term risk, CDTX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CDTX vs RETA Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas RETA's P/E ratio is -66.29. In terms of profitability, CDTX's ROE is -0.37%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CDTX is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CDTX vs MIRM Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas MIRM's P/E ratio is -7.78. In terms of profitability, CDTX's ROE is -0.37%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, CDTX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CDTX vs BLTE Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas BLTE's P/E ratio is -84.82. In terms of profitability, CDTX's ROE is -0.37%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, CDTX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
CDTX vs ERAS Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ERAS's P/E ratio is -19.51. In terms of profitability, CDTX's ROE is -0.37%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, CDTX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
CDTX vs CGON Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CGON's P/E ratio is -30.55. In terms of profitability, CDTX's ROE is -0.37%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CDTX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CDTX vs CNTA Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CDTX's ROE is -0.37%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CDTX is similarly volatile compared to CNTA. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CDTX vs XENE Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas XENE's P/E ratio is -13.33. In terms of profitability, CDTX's ROE is -0.37%, compared to XENE's ROE of -0.49%. Regarding short-term risk, CDTX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CDTX vs LGND Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas LGND's P/E ratio is 34.48. In terms of profitability, CDTX's ROE is -0.37%, compared to LGND's ROE of +0.16%. Regarding short-term risk, CDTX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CDTX vs SRRK Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas SRRK's P/E ratio is -13.17. In terms of profitability, CDTX's ROE is -0.37%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, CDTX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CDTX vs PTCT Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas PTCT's P/E ratio is -29.19. In terms of profitability, CDTX's ROE is -0.37%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, CDTX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check PTCT's competition here
Abcam plc (NASDAQ: ABCM)
CDTX vs ABCM Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CDTX's ROE is -0.37%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CDTX is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CDTX vs ISEE Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CDTX's ROE is -0.37%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CDTX is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CDTX vs APLS Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas APLS's P/E ratio is 38.35. In terms of profitability, CDTX's ROE is -0.37%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CDTX is less volatile compared to APLS. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CDTX vs TVTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas TVTX's P/E ratio is -254.05. In terms of profitability, CDTX's ROE is -0.37%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, CDTX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CDTX vs TERN Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas TERN's P/E ratio is -51.41. In terms of profitability, CDTX's ROE is -0.37%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CDTX is less volatile compared to TERN. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CDTX vs DFTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas DFTX's P/E ratio is N/A. In terms of profitability, CDTX's ROE is -0.37%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, CDTX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
CDTX vs DYN Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas DYN's P/E ratio is -7.82. In terms of profitability, CDTX's ROE is -0.37%, compared to DYN's ROE of -0.64%. Regarding short-term risk, CDTX is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CDTX vs CRSP Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CRSP's P/E ratio is -9.39. In terms of profitability, CDTX's ROE is -0.37%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, CDTX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CDTX vs FOLD Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CDTX's ROE is -0.37%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CDTX is similarly volatile compared to FOLD. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CDTX vs AKRO Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CDTX's ROE is -0.37%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, CDTX is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CDTX vs DNTH Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas DNTH's P/E ratio is -25.89. In terms of profitability, CDTX's ROE is -0.37%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, CDTX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CDTX vs ALPN Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CDTX's ROE is -0.37%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CDTX is less volatile compared to ALPN. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
CDTX vs ACAD Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ACAD's P/E ratio is 12.68. In terms of profitability, CDTX's ROE is -0.37%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, CDTX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
CDTX vs CAI Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CAI's P/E ratio is -86.19. In terms of profitability, CDTX's ROE is -0.37%, compared to CAI's ROE of +0.06%. Regarding short-term risk, CDTX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
CDTX vs MANE Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas MANE's P/E ratio is -33.36. In terms of profitability, CDTX's ROE is -0.37%, compared to MANE's ROE of -0.84%. Regarding short-term risk, CDTX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
CDTX vs OPT Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas OPT's P/E ratio is -1.52. In terms of profitability, CDTX's ROE is -0.37%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CDTX is similarly volatile compared to OPT. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
CDTX vs PRTC Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas PRTC's P/E ratio is -3.78. In terms of profitability, CDTX's ROE is -0.37%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, CDTX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
CDTX vs CELC Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CELC's P/E ratio is -22.15. In terms of profitability, CDTX's ROE is -0.37%, compared to CELC's ROE of -2.45%. Regarding short-term risk, CDTX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CDTX vs EWTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas EWTX's P/E ratio is -23.15. In terms of profitability, CDTX's ROE is -0.37%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, CDTX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CDTX vs MRTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CDTX's ROE is -0.37%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CDTX is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
CDTX vs ELVN Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ELVN's P/E ratio is -32.82. In terms of profitability, CDTX's ROE is -0.37%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, CDTX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
CDTX vs CPRX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CPRX's P/E ratio is 12.30. In terms of profitability, CDTX's ROE is -0.37%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CDTX is similarly volatile compared to CPRX. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
CDTX vs RYZB Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CDTX's ROE is -0.37%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CDTX is less volatile compared to RYZB. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
CDTX vs CBAY Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CDTX's ROE is -0.37%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CDTX is less volatile compared to CBAY. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
CDTX vs VKTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas VKTX's P/E ratio is -7.67. In terms of profitability, CDTX's ROE is -0.37%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, CDTX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
CDTX vs DNLI Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas DNLI's P/E ratio is -7.99. In terms of profitability, CDTX's ROE is -0.37%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, CDTX is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
CDTX vs ORKA Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ORKA's P/E ratio is -49.75. In terms of profitability, CDTX's ROE is -0.37%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, CDTX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CDTX vs ADPT Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ADPT's P/E ratio is -41.80. In terms of profitability, CDTX's ROE is -0.37%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, CDTX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
CDTX vs ALMS Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ALMS's P/E ratio is -7.39. In terms of profitability, CDTX's ROE is -0.37%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, CDTX is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
CDTX vs RCUS Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas RCUS's P/E ratio is -8.66. In terms of profitability, CDTX's ROE is -0.37%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, CDTX is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
CDTX vs SWTX Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CDTX's ROE is -0.37%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, CDTX is similarly volatile compared to SWTX. This indicates similar risk in terms of short-term price fluctuations for CDTX.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
CDTX vs ARQT Comparison August 2026
Cidara Therapeutics, Inc. (NASDAQ: CDTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDTX stands at 5.6B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, CDTX is priced at $221.38 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDTX currently has a P/E ratio of -19.77, whereas ARQT's P/E ratio is -933.00. In terms of profitability, CDTX's ROE is -0.37%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, CDTX is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for CDTX.Check ARQT's competition here